{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:17:21Z","timestamp":1791123441194,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,11,29]],"date-time":"2013-11-29T00:00:00Z","timestamp":1385683200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2013.63","type":"journal-article","created":{"date-parts":[[2013,11,29]],"date-time":"2013-11-29T14:15:15Z","timestamp":1385734515000},"page":"e166-e166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases"],"prefix":"10.1038","volume":"3","author":[{"given":"F","family":"Hayakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Ohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kurahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,29]]},"reference":[{"key":"BFbcj201363_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0092-8674(00)81277-5","volume":"84","author":"JN Ihle","year":"1996","unstructured":"Ihle JN . STATs: signal transducers and activators of transcription. Cell 1996; 84: 331\u2013334.","journal-title":"Cell"},{"key":"BFbcj201363_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","volume":"16","author":"WJ Leonard","year":"1998","unstructured":"Leonard WJ, O'Shea JJ . Jaks and STATs: biological implications. Annu Rev Immunol 1998; 16: 293\u2013322.","journal-title":"Annu Rev Immunol"},{"key":"BFbcj201363_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1196\/annals.1377.002","volume":"1086","author":"F Hayakawa","year":"2006","unstructured":"Hayakawa F, Naoe T . SFK-STAT pathway: an alternative and important way to malignancies. Ann NY Acad Sci 2006; 1086: 213\u2013222.","journal-title":"Ann NY Acad Sci"},{"key":"BFbcj201363_CR4","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0092-8674(00)81443-9","volume":"93","author":"X Chen","year":"1998","unstructured":"Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE, Kuriyan J Jr . Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 1998; 93: 827\u2013839.","journal-title":"Cell"},{"key":"BFbcj201363_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/0092-8674(94)90357-3","volume":"76","author":"K Shuai","year":"1994","unstructured":"Shuai K, Horvath CM, Huang LH, Qureshi SA, Cowburn D, Darnell JE Jr . Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 1994; 76: 821\u2013828.","journal-title":"Cell"},{"key":"BFbcj201363_CR6","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1128\/MCB.18.5.2553","volume":"18","author":"JF Bromberg","year":"1998","unstructured":"Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE Jr . Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998; 18: 2553\u20132558.","journal-title":"Mol Cell Biol"},{"key":"BFbcj201363_CR7","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1128\/MCB.18.5.2545","volume":"18","author":"J Turkson","year":"1998","unstructured":"Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R . Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998; 18: 2545\u20132552.","journal-title":"Mol Cell Biol"},{"key":"BFbcj201363_CR8","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1128\/MCB.19.2.1401","volume":"19","author":"D Besser","year":"1999","unstructured":"Besser D, Bromberg JF, Darnell JE Jr, Hanafusa H . A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. Mol Cell Biol 1999; 19: 1401\u20131409.","journal-title":"Mol Cell Biol"},{"key":"BFbcj201363_CR9","doi-asserted-by":"publisher","first-page":"28065","DOI":"10.1074\/jbc.273.43.28065","volume":"273","author":"CS Zong","year":"1998","unstructured":"Zong CS, Zeng L, Jiang Y, Sadowski HB, Wang LH . Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth. J Biol Chem 1998; 273: 28065\u201328072.","journal-title":"J Biol Chem"},{"key":"BFbcj201363_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1126\/science.7604283","volume":"269","author":"TS Migone","year":"1995","unstructured":"Migone TS, Lin JX, Cereseto A, Mulloy JC, O'Shea JJ, Franchini G et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 1995; 269: 79\u201381.","journal-title":"Science"},{"key":"BFbcj201363_CR11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1182\/blood.V88.3.809.809","volume":"88","author":"RM Weber-Nordt","year":"1996","unstructured":"Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R et al. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 1996; 88: 809\u2013816.","journal-title":"Blood"},{"key":"BFbcj201363_CR12","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1126\/science.7569929","volume":"269","author":"NN Danial","year":"1995","unstructured":"Danial NN, Pernis A, Rothman PB . Jak-STAT signaling induced by the v-abl oncogene. Science 1995; 269: 1875\u20131877.","journal-title":"Science"},{"key":"BFbcj201363_CR13","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1038\/sj.onc.1203484","volume":"19","author":"NN Danial","year":"2000","unstructured":"Danial NN, Rothman P . JAK-STAT signaling activated by Abl oncogenes. Oncogene 2000; 19: 2523\u20132531.","journal-title":"Oncogene"},{"key":"BFbcj201363_CR14","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood.V94.3.1108.415k07_1108_1112","volume":"94","author":"RP de Groot","year":"1999","unstructured":"de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L . STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 1999; 94: 1108\u20131112.","journal-title":"Blood"},{"key":"BFbcj201363_CR15","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1084\/jem.189.8.1229","volume":"189","author":"M Nieborowska-Skorska","year":"1999","unstructured":"Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B et al. Signal transducer and activator of transcription (STAT)5 activation by BCR\/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR\/ABL and is required for leukemogenesis. J Exp Med 1999; 189: 1229\u20131242.","journal-title":"J Exp Med"},{"key":"BFbcj201363_CR16","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood.V95.6.2118","volume":"95","author":"C Sillaber","year":"2000","unstructured":"Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD . STAT5 activation contributes to growth and viability in Bcr\/Abl-transformed cells. Blood 2000; 95: 2118\u20132125.","journal-title":"Blood"},{"key":"BFbcj201363_CR17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/sj.onc.1203354","volume":"19","author":"F Hayakawa","year":"2000","unstructured":"Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000; 19: 624\u2013631.","journal-title":"Oncogene"},{"key":"BFbcj201363_CR18","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","volume":"96","author":"M Mizuki","year":"2000","unstructured":"Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000; 96: 3907\u20133914.","journal-title":"Blood"},{"key":"BFbcj201363_CR19","doi-asserted-by":"publisher","first-page":"18962","DOI":"10.1073\/pnas.0509714102","volume":"102","author":"X Lu","year":"2005","unstructured":"Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 2005; 102: 18962\u201318967.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201363_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","volume":"98","author":"JF Bromberg","year":"1999","unstructured":"Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. Stat3 as an oncogene. Cell 1999; 98: 295\u2013303.","journal-title":"Cell"},{"key":"BFbcj201363_CR21","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1128\/MCB.18.7.3871","volume":"18","author":"M Onishi","year":"1998","unstructured":"Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, McMahon M et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol 1998; 18: 3871\u20133879.","journal-title":"Mol Cell Biol"},{"key":"BFbcj201363_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/13543780802565791","volume":"18","author":"P Yue","year":"2009","unstructured":"Yue P, Turkson J . Targeting STAT3 in cancer: how successful are we? Exp Opin Invest Drug 2009; 18: 45\u201356.","journal-title":"Exp Opin Invest Drug"},{"key":"BFbcj201363_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nature11303","volume":"489","author":"P Koppikar","year":"2012","unstructured":"Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012; 489: 155\u2013159.","journal-title":"Nature"},{"key":"BFbcj201363_CR24","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1182\/blood-2009-01-199307","volume":"114","author":"Y Shiotsu","year":"2009","unstructured":"Shiotsu Y, Kiyoi H, Ishikawa Y, Tanizaki R, Shimizu M, Umehara H et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR\/ABL translocation. Blood 2009; 114: 1607\u20131617.","journal-title":"Blood"},{"key":"BFbcj201363_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.canlet.2013.02.010","volume":"335","author":"MJ Kim","year":"2013","unstructured":"Kim MJ, Nam HJ, Kim HP, Han SW, Im SA, Kim TY et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2\/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett 2013; 335: 145\u2013152.","journal-title":"Cancer Lett"},{"key":"BFbcj201363_CR26","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/onc.2010.554","volume":"30","author":"S Kurahashi","year":"2011","unstructured":"Kurahashi S, Hayakawa F, Miyata Y, Yasuda T, Minami Y, Tsuzuki S et al. PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML. Oncogene 2011; 30: 1822\u20131830.","journal-title":"Oncogene"},{"key":"BFbcj201363_CR27","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1349-7006.2009.01440.x","volume":"101","author":"R Tanizaki","year":"2010","unstructured":"Tanizaki R, Nomura Y, Miyata Y, Minami Y, Abe A, Hanamura A et al. Irrespective of CD34 expression, lineage-committed cell fraction reconstitutes and re-establishes transformed Philadelphia chromosome-positive leukemia in NOD\/SCID\/IL-2Rgammac\u2212\/\u2212 mice. Cancer Sci 2010; 101: 631\u2013638.","journal-title":"Cancer Sci"},{"key":"BFbcj201363_CR28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/sj.leu.2404547","volume":"21","author":"M Okamoto","year":"2007","unstructured":"Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A et al. Lyn is an important component of the signal transduction pathway specific to FLT3\/ITD and can be a therapeutic target in the treatment of AML with FLT3\/ITD. Leukemia 2007; 21: 403\u2013410.","journal-title":"Leukemia"},{"key":"BFbcj201363_CR29","doi-asserted-by":"publisher","first-page":"e13056","DOI":"10.1200\/jco.2010.28.15_suppl.e13056","volume":"28","author":"D Oh","year":"2010","unstructured":"Oh D, Han S, Kim TM, Lee S, Kim T, Heo DS et al. A phase I, open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2010; 28: e13056.","journal-title":"J Clin Oncol"},{"key":"BFbcj201363_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387\u2013397.","journal-title":"Cancer Cell"},{"key":"BFbcj201363_CR31","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1084\/jem.183.3.811","volume":"183","author":"N Carlesso","year":"1996","unstructured":"Carlesso N, Frank DA, Griffin JD . Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl. J Exp Med 1996; 183: 811\u2013820.","journal-title":"J Exp Med"},{"key":"BFbcj201363_CR32","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.1182\/blood-2008-05-156422","volume":"113","author":"J Zhou","year":"2009","unstructured":"Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 2009; 113: 4052\u20134062.","journal-title":"Blood"},{"key":"BFbcj201363_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1517\/13543776.2011.539205","volume":"21","author":"BD Page","year":"2011","unstructured":"Page BD, Ball DP, Gunning PT . Signal transducer and activator of transcription 3 inhibitors: a patent review. Exp Opin Ther Patent 2011; 21: 65\u201383.","journal-title":"Exp Opin Ther Patent"},{"key":"BFbcj201363_CR34","first-page":"67","volume":"13","author":"SY Lai","year":"2010","unstructured":"Lai SY, Johnson FM . Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Update Rev Comment Antimicrob Anticancer Chemother 2010; 13: 67\u201378.","journal-title":"Drug Resist Update Rev Comment Antimicrob Anticancer Chemother"},{"key":"BFbcj201363_CR35","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1158\/0008-5472.CAN-10-2380","volume":"71","author":"A Scuto","year":"2011","unstructured":"Scuto A, Kujawski M, Kowolik C, Krymskaya L, Wang L, Weiss LM et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res 2011; 71: 3182\u20133188.","journal-title":"Cancer Res"},{"key":"BFbcj201363_CR36","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070\u20131079.","journal-title":"Blood"},{"key":"BFbcj201363_CR37","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690\u2013698.","journal-title":"Blood"},{"key":"BFbcj201363_CR38","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","volume":"7","author":"NN Bewry","year":"2008","unstructured":"Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA . Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008; 7: 3169\u20133175.","journal-title":"Mol Cancer Ther"},{"key":"BFbcj201363_CR39","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1182\/blood-2010-04-261867","volume":"116","author":"T Kindler","year":"2010","unstructured":"Kindler T, Lipka DB, Fischer T . FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010; 116: 5089\u20135102.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bcj201363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bcj201363","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:46:51Z","timestamp":1672958811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,29]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2013,11]]}},"alternative-id":["BFbcj201363"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2013.63","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,29]]},"assertion":[{"value":"7 August 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TN received research funding from Otsuka Pharmaceutical Co., Ltd, Kyowa Hakko Kirin Co., Ltd., Wyeth and Chugai Pharmaceutical Co., Ltd. KS, YH, NH and NO are employees of Otsuka Pharmaceutical Co., Ltd., whose product was studied in this work. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}